BioSelective Capital Investments Acquires BioDuro's Irvine Drug Product Operations to Form Forma Life Sciences

Novo Nordisk Acquires Forma Therapeutics for $1.1 billion

September 1, 2022

Biotechnology

Novo Nordisk agreed to acquire clinical-stage biopharmaceutical company Forma Therapeutics for $20 per share in cash, valuing the deal at approximately $1.1 billion. The purchase adds Forma's lead candidate etavopivat and strengthens Novo Nordisk's pipeline in sickle cell disease and other rare blood disorders; the transaction is being effected via a tender offer and is expected to close in Q4 2022, subject to customary conditions and regulatory approvals.

Satori Capital Acquires Formulife; Brookside Capital Provides Financing Support

July 15, 2021

Food & Beverage

Satori Capital has acquired Formulife, a specialty contract manufacturer of custom-formulated nutritional supplements based in Allen, Texas. Brookside Capital Partners provided a unitranche debt facility and an equity co-investment to facilitate the transaction; Satori will use part of the investment to complete a major expansion of Formulife's production facility to more than double capacity and reduce customer lead times.

Adare Pharma Solutions Acquires Frontida BioPharm

December 1, 2021

Pharmaceuticals

Adare Pharma Solutions, a PE-backed contract development and manufacturing organization (CDMO), has acquired Frontida BioPharm, a vertically integrated CDMO focused on oral formulations. The deal expands Adare’s capabilities—including high-potency compound handling and packaging services—and increases its manufacturing footprint; Adare is backed by Thomas H. Lee Partners and Frazier Healthcare Partners.

Riverside-backed BioDue Acquires Biokosmes and Rolf Kullgren from Venture Life

May 12, 2025

Medical Devices

BioDue S.p.A., a Riverside-backed Italian CDMO, has signed a definitive agreement to acquire Biokosmes S.r.l. and the Rolf Kullgren manufacturing operations (Venture Life Manufacturing AB) from Venture Life Group plc. The add-on expands BioDue’s CDMO footprint—adding manufacturing sites in Northern Italy and Sweden (bringing BioDue to seven plants), broadening its medical device, cosmetics and supplements capabilities, and includes a long-term manufacturing agreement under which Venture Life will remain a customer.

Curia Acquires LakePharma to Expand Biologics R&D and Manufacturing Capabilities

February 14, 2022

Biotechnology

Curia (formerly AMRI) has acquired LakePharma Inc., a US-based biologics contract research, development and manufacturing organization with operations in California, Massachusetts and Texas. The deal adds LakePharma's six facilities and ~235 employees to Curia's global network, creating expanded end-to-end capabilities from discovery through GMP manufacturing for biologics.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.